Welcome to LookChem.com Sign In|Join Free
  • or
N-(1-ADAMANTYL)HYDRAZINECARBOXAMIDE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

26496-36-6

Post Buying Request

26496-36-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

26496-36-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 26496-36-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,4,9 and 6 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 26496-36:
(7*2)+(6*6)+(5*4)+(4*9)+(3*6)+(2*3)+(1*6)=136
136 % 10 = 6
So 26496-36-6 is a valid CAS Registry Number.
InChI:InChI=1/C11H19N3O/c12-14-10(15)13-11-4-7-1-8(5-11)3-9(2-7)6-11/h7-9H,1-6,12H2,(H2,13,14,15)

26496-36-6Downstream Products

26496-36-6Relevant academic research and scientific papers

Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease

Palanimuthu, Duraippandi,Wu, Zhixuan,Jansson, Patric J.,Braidy, Nady,Bernhardt, Paul V.,Richardson, Des R.,Kalinowski, Danuta S.

, p. 7190 - 7205 (2018)

Alzheimer's disease (AD) is characterized by multiple pathological hallmarks, including β-amyloid aggregation, oxidative stress, and metal dys-homeostasis. In the absence of treatments addressing its multi-factorial pathology, we designed novel multi-functional adamantane-based semicarbazones and hydrazones (1-12) targeting AD hallmarks. Of these, 2-pyridinecarboxaldehyde (N-adamantan-1-yl)benzoyl-4-amidohydrazone (10) was identified as the lead compound, which demonstrated: (1) pronounced iron chelation efficacy; (2) attenuation of CuII-mediated β-amyloid aggregation; (3) low cytotoxicity; (4) inhibition of oxidative stress; and (5) favorable characteristics for effective blood-brain barrier permeation. Structure-activity relationships revealed that pyridine-derived hydrazones represent a promising pharmacophore for future design strategies due to their ability to bind critical FeII pools. Collectively, the unique multi-functional activity of these agents provides a novel therapeutic strategy for AD treatment.

N-Substituted S-Alkyl Carbamothioates in the Synthesis of Nitrogen-containing Functional Derivatives of the Adamantane Series

Klimochkin, Yu. N.,Ivleva

, p. 1281 - 1288 (2021/09/30)

Abstract: A series of new asymmetric ureas, urethanes, and other derivatives of the framework structure have been synthesized by the reactions of adamantan-1-yl isocyanate generated in situ by the thermolysis of carbamothioates with nitrogen-containing nucleophiles and alcohols.

Highly Regioselective Carbamoylation of Electron-Deficient Nitrogen Heteroarenes with Hydrazinecarboxamides

He, Zeng-Yang,Huang, Chao-Fan,Tian, Shi-Kai

, p. 4850 - 4853 (2017/09/23)

The use of hydrazinecarboxamides as a new class of carbamoylating agents has been established through the dehydrazinative Minisci reaction of electron-deficient nitrogen heteroarenes. A wide range of electron-deficient nitrogen heteroarenes, including isoquinoline, quinoline, pyridine, phenanthridine, quinoxaline, and phthalazine, underwent copper/acid-catalyzed oxidative carbamoylation with hydrazinecarboxamide hydrochlorides to afford structurally diverse nitrogen-heteroaryl carboxamides as single regioisomers in moderate to excellent yields. The functional group tolerance was substantially demonstrated in the direct carbamoylation of quinine obviating multistep sequences involving protecting groups and prefunctionalization of the heterocycle.

ADAMANTANE COMPOUNDS

-

Page/Page column 16; 40; 41, (2018/01/20)

The present invention relates to new multi-functional compounds that are useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease, to the preparation of the compounds, and to compositions including the compounds. The present invention also relates to the use of the compounds, as well as compositions including the compounds, in treating or preventing neurodegenerative diseases.

Adamantane derivatives, part III*: Synthesis of some aminoadamantanes as novel antitumor aqents

El-Sherbeny,Youssef,Mahran

, p. 195 - 209 (2007/10/03)

New series of 1-(1-adamantyl)semicarbazide 3a, 1-(1-adamantyl)-4-(4-substituted phenyl)semicarbazides 3b-e, 1-(1-adamantyl)-3-(substituted aminosulfonyl)ureas 5a-g, 1-(1-adamantyl)-4-(1-adamantylamino-methylene)-semicarbazide 7, 1-(1-adamantyl)-4-(1-adama

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 26496-36-6